Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intercept Pharmaceuticals
None provided
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female age 18 to 70 years.
Stable dose of ursodeoxycholic acid (URSO, UDCA) for at least 6 months prior to screening.
Female patients must be postmenopausal, surgically sterile, or prepared to use 2 methods of contraception with all sexual partners during the study and for 14 days after the end of dosing.
Male patients must be prepared to use 2 methods of contraception with all sexual partners during the study and for 14 days after the end of the dosing.
Proven or likely PBC, as demonstrated by the patient presenting with at least 2 of the following 3 diagnostic factors:
1. History of increased AP levels for at least 6 months prior to Day 0
2. Positive AMA titer (\>1:40 titer on immunofluorescence or M2 positive by ELISA) or PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive)
3. Liver biopsy consistent with PBC.
Screening AP value between 1.5 and 10 × ULN.
You may not be if
Administration of the following drugs at any time during the 3 months prior to screening for the study: colchicine, methotrexate, azathioprine, or systemic corticosteroids.
History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).
History or presence of other concomitant liver diseases including hepatitis due to hepatitis B or C virus (HCV, HBV) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease, definite autoimmune liver disease or biopsy proven nonalcoholic steatohepatitis (NASH).